137MO Outcomes of patients (pts) treated with ESCAT I–II targeted therapies (TT) in early phase clinical trials (EPCTs)
TT and next-generation sequencing (NGS) have transformed cancer care, enabling personalized treatment approaches based on tumor molecular profiles. We evaluated outcomes of pts treated with ESCAT 1–2 matched agents in EPCTs within the 360 RESISTANCE (360R) study.
Authors
- G. Pretelli (ORCID: https://orcid.org/0000-0002-5550-1211)
- Vladimir Galvao (ORCID: https://orcid.org/0009-0007-8139-8215)
- M.J. Lostes Bardaji
- Marta Sanz (ORCID: https://orcid.org/0009-0004-7933-1298)
- A. Oberoi (ORCID: https://orcid.org/0009-0003-2207-6524)
- Oriol Mirallas (ORCID: https://orcid.org/0000-0002-8492-5195)
- Irene Braña
- Elena Garralda
- V. Sanchez Perez
- P. Nuciforo
- R. Dienstmann
- F. Bruzzone
- G. Alonso Casal
- G. Villacampa
- V. Navarro
- A. Hernando Calvo
- S. Aguilar Izquierdo
- J. Tabernero
- A. Vivancos
- M. Vieito
Institutions
- Hebron University (PS)
- Vall d'Hebron Institut de Recerca (ES)
- Vall d'Hebron Hospital Universitari (ES)
- CIBBIM-Nanomedicine (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2026-04-01
- DOI
- https://doi.org/10.1016/j.esmoop.2026.106280
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- “la Caixa” Foundation